top of page
Cannabinoid-Translational-Neuroscience-&-Behavior-Lab-logo

Publications

From the past 5 years...

  1. Lacovic J, Dey S, Ward SJ, Greif NH, Tweedie D, Beiranvand N, Saini U, Chatterjee D, and Varadhachary A. Pharmacological characterization and preclinical evaluation of 11h: a novel, brain-penetrant PDE4 inhibitor for neurological disorders. Front. Pharmacol., 07 January 2026 Sec. Experimental Pharmacology and Drug Discovery, Volume 16 – 2025,, https://doi.org/10.3389/fphar.2025.1720327

  2. Weiss M, Giaddui M, Kjelstrom S, Gary J, Ward SJ, Burrell J, Diguilio K, Bidas G, Erebor E, Meske S, Saeed L, Windawi S, Aliano Ruiz K, Ghaneie A, Hibbs J, Marks J, Holtz D, Ali Z, Shevade A, Sabol J, Ciocca R, Zeger E, Gilman P, Larson S, Shimamoto S and Martinez D (2025) Combination CBD/THC in the management of chemotherapy-induced peripheral neuropathy: a randomized double blind controlled trial. Front. Oncol. 15:1590168. doi: 10.3389/fonc.2025.1590168.

  3. Ippolito MJ, Maddox C, Inam A, Wimmer ME, Ward SJ. Prevention of Allodynia and Hyperalgesia by Cannabidiol in a Rat Model of Chemotherapy-Induced Peripheral Neuropathy. JOVE March 2025 in press.

  4. Brenneman DE, Petkanas D, Ippolito M, Ward SJ. Effect of Fatty Acyl Composition for Lysophosphatidylinositol on Neuroinflammatory Responses in Primary Neuronal Cultures. J Mol Neurosci. 2025 Mar 14;75(1):35.

  5. Ippolito MJ, Kinney W, Brenneman DE, Hayduk SA, Ward SJ. KLS-13019, a novel structural analogue of cannabidiol (CBD) and GPR55 receptor antagonist, Prevents and Reverses Chemotherapy-Induced Peripheral Neuropathy (CIPN) in Rats. J Pharmacol Exp Ther. 2024 Oct 18;391(2):231-240.

  6. Hayduk, SA, Hughes AC, Winter R, Milton MD, Ward SJ. Single and combined effects of cannabigerol (CBG) and cannabidiol (CBD) in mouse models of oxaliplatin-associated mechanical sensitivity, opioid antinociception, and naloxone-precipitated opioid withdrawal. Biomedicines. 2024 May 22;12(6):1145. 

  7. Li H, Ward SJ. Paclitaxel-associated mechanical sensitivity and neuroinflammation are sex-, time-, and site- specific and prevented by cannabigerol administration in C57Bl/6 mice. Int J Mol Sci 2024 Apr 12;25(8):4277.

  8.  Brenneman DE, Kinney WA, McDonnell ME, Ippolito MJ, Ward SJ. Knockdown siRNA targeting GPR55 reveals significant differences between the anti- inflammatory actions of KLS-13019 and cannabidiol. J Mol Neurosci. 2024 Apr 11;74(2):41.

  9. Inan S, Ward SH, Baltazar CT, Peruggia GA, Javed E, Nayak AP. Epicutaneous Sensitization to the Phytocannabinoid β-Caryophyllene Induces Pruritic Inflammation. International Journal of Molecular Sciences Pub Date: 2023-09-20 , DOI:10.3390/ijms241814328

  10. Farkas DJ, Cooper ZD, Heydari LN, Hughes AC, Rawls SM, Ward SJ. Kratom Alkaloids, Cannabinoids, and Chronic Pain: Basis of Potential Utility and Role in Therapy. Cannabis Cannabinoid Res. 2023 Jul 19. doi: 10.1089/can.2023.0064.

  11. Farkas DJ, Inan S, Heydari LN, Johnson CT, Zhao P, Bradshaw HB, Ward SJ, Rawls SM. Cannabinoid mechanisms contribute to the therapeutic efficacy of the kratom alkaloid mitragynine against neuropathic, but not inflammatory pain. Life Science Volume 328, 2023, 121878, https://doi.org/10.1016/j.lfs.2023.121878.

  12. Laks EY, Li H, Ward SJ. Non-Psychoactive Cannabinoid Modulation of Nociception and Inflammation Associated with a Rat Model of Pulpitis. Biomolecules 2023, 13(5), 846; https://doi.org/10.3390/biom13050846.

  13. Farkas DJ, Foss JD, Ward SJ, Rawls SM. Kratom alkaloid mitragynine: Inhibition of chemotherapy-induced peripheral neuropathy in mice is dependent on sex and active adrenergic and opioid receptors. IBRO Neurosci Rep. 2022  Aug 30;13:198-206. doi: 10.1016/j.ibneur.2022.08.007. eCollection 2022 Dec. PMID: 36093282 Free PMC article.

  14. Brenneman DE, Kinney WA, McDonnell ME, Zhao P, Abood ME, Ward SJ. Anti-inflammatory properties of KLS-13019: a novel GPR55 antagonist for dorsal root ganglion and hippocampal cultures. Journal of Molecular Neuroscience, 2022 Sep;72(9):1859-1874. doi: 10.1007/s12031-022-02038-2. Epub 2022 Jul 2.

  15. Ward SJ, Lichtman AH, Piomelli D, Parker LA. Cannabinoids and Cancer Chemotherapy-Associated Adverse Effects. J Natl Cancer Inst Monogr. 2021 Nov 28;2021(58):78-85. doi: 10.1093/jncimonographs/lgab007. PMID: 34850893; PMCID: PMC8848502.

  16. Reichenbach ZW, DiMatteo K, Rajakaruna S, Ambrose D, Cornwell WD, Tallarida RJ, Rogers T, Liu-Chen LY, Tuma RF, Ward SJ. Modulation of Morphine Analgesia, Antinociceptive Tolerance, and Mu-Opioid Receptor Binding by the Cannabinoid CB2 Receptor Agonist O-1966. Front. Pharmacol., 2022 Apr 21;13:803331.

  17. Foss JD, Farkas DJ, Huynh LM, Kinney WA, Brenneman DE, Ward SJ. Behavioral and pharmacological effects of cannabidiol (CBD) and the CBD analogue KLS-13019 in mouse models of pain and reinforcement. Br J Pharmacol. 2021 Aug;178(15):3067-3078.

  18. Yokubaitis C, Jessani H, Li H, Amodea A, and Ward SJ. Effects of Cannabidiol and Beta-Caryophyllene Alone or in Combination in a Mouse Model of Permanent Ischemia. In Special Issue on Pharmacological Study on Neuromodulatory Effects of Plant Extract, International Journal of Molecular Sciences 2021 Mar 11;22(6):2866.

  19. Ippolito M, Ward SJ. Medical Cannabis for Ulcerative Colitis and Inflammatory Bowel Disease: A Patient’s Insight. Published Online in Americal Journal of Endocannabinoid Medicine March 2021 3:1

bottom of page